false
OasisLMS
Catalog
SCCM Resource Library
180-Day Outcomes in Critically Ill Patients with C ...
180-Day Outcomes in Critically Ill Patients with COVID-19 in the REMAP-CAP Randomized Clinical Trial
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
The speaker presented the results of the Remap-Cap trial, which is a platform trial evaluating multiple treatments for community-acquired pneumonia (CAP) and COVID-19. They focused on the outcomes of the critically ill patients in the trial. The trial used a Bayesian design and randomized patients into different domains or treatment groups. The results showed that interleukin-6 receptor antagonists and antiplatelets had a high probability of improving patient outcomes at six months, with reductions in mortality and no significant impact on quality of life or disability. However, some interventions, such as hydroxychloroquine and combination antiviral therapy, were associated with increased mortality. The speaker emphasized the importance of measuring longer-term outcomes, such as survival free of major disability and with an acceptable quality of life, which can be more important to patients. They concluded that short-term outcomes can be used to make rapid changes and recommendations during a pandemic, as they are associated with longer-term outcomes.
Asset Subtitle
Research, Infection, 2023
Asset Caption
Type: two-hour concurrent | Late-Breaking Studies Affecting Patient Outcomes (SessionID 9000007)
Meta Tag
Content Type
Presentation
Knowledge Area
Research
Knowledge Area
Infection
Membership Level
Professional
Membership Level
Select
Tag
Outcomes Research
Tag
COVID-19
Year
2023
Keywords
Remap-Cap trial
community-acquired pneumonia
COVID-19
interleukin-6 receptor antagonists
antiplatelets
×
Please select your language
1
English